Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine (Primary) ; Brimonidine/loteprednol-etabonate (Primary) ; Carmellose; Corticosteroid
  • Indications Dry eyes
  • Focus Adverse reactions; Proof of concept
  • Sponsors Ocugen

    • Most Recent Events

    • 23 Oct 2018 According to an Ocugen media release, data from the trial will be presented at the 2018 Annual Meeting of The American Academy of Ophthalmology (AAO).
    • 09 Jul 2018 Status changed from recruiting to completed.
    • 20 Mar 2018 According to an Ocugen media release, this study met its primary endpoint of tolerability over a 12-week period.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top